First Time Loading...

Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.49 USD 8.76% Market Closed
Updated: May 7, 2024

Akebia Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Akebia Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Akebia Therapeutics Inc
NASDAQ:AKBA
Revenue
$194.6m
CAGR 3-Years
-13%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Akebia Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Akebia Therapeutics Inc

Not Available

Breakdown by Segments
Akebia Therapeutics Inc

Total Revenue: 194.6m USD
100%
Product Revenue, Net: 170.3m USD
87.5%
License, Collaboration And Other Revenue: 24.3m USD
12.5%

See Also

What is Akebia Therapeutics Inc's Revenue?
Revenue
194.6m USD

Based on the financial report for Dec 31, 2023, Akebia Therapeutics Inc's Revenue amounts to 194.6m USD.

What is Akebia Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-1%

Over the last year, the Revenue growth was -33%. The average annual Revenue growth rates for Akebia Therapeutics Inc have been -13% over the past three years , -1% over the past five years .